Newsroom | 60926 results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated finan...

TOKYO--(BUSINESS WIRE)--Space Quarters Inc. has successfully conducted aircraft-based demonstration tests of space welding for metals and lunar regolith-based construction materials under space-equivalent ultra-high vacuum and simulated microgravity and lunar gravity. Under conditions comparable to construction in space, the company confirmed sound joints and sufficient bonding strength. Space Welding Demonstration through Aircraft-Based Testing A high-vacuum chamber was mounted on an aircraft...

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under th...

MERRITT ISLAND, Fla.--(BUSINESS WIRE)--X-lumin has successfully demonstrated a roundtrip optical transmission from its 15cm Optical Ground Terminal (OGT) to a retroreflector-equipped LEO satellite, and back, with the ability to track downlink signals that are 106 times dimmer than the current standard of 25µW/m2. The demonstration was repeated over multiple passes during recent testing, marking the first time a portable, low SWaP (Size, Weight, Power) terminal has closed a roundtrip optical lin...

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), un’azienda biotecnologica globale che dà impulso alla ricerca e sviluppo di farmaci innovativi basati su anticorpi impiegando tecnologie all’avanguardia, oggi ha annunciato una collaborazione strategica con Moonlight Bio, Inc., società biotecnologica con sede a Seattle, pioniera nelle terapie cellulari all’avanguardia. Questa collaborazione mira a sviluppare terapie cellulari all’ava...

LAS VEGAS--(BUSINESS WIRE)--Roseman Bioventures aims to accelerate the commercialization of life science innovations and expand the Nevada biotech ecosystem....

シンガポール--(BUSINESS WIRE)--（ビジネスワイヤ） -- HJS Foundation（Human Judgment Systems Foundation）は、2つの補完的なソリューション「Judgment Event Protocol（JEP）」と「Human Judgment Structure（HJS）」フレームワークを公開しました。ミニマリストなオープン・スタンダードであるJEPは、航空機のブラックボックスと同様に、改ざんできないAIの意思決定における説明責任の記録を生成します。そして、HJSは人間の判断ロジックをAIの運用プロセスに組み込みます。両者を組み合わせることで、「人間による監視」を規制上の要件から検証可能な技術的事実へと転換し、AIの説明責任に対するオプションの技術的ソリューションを提供します。 これで、融資審査、医療診断、入国審査などのAIによる意思決定が人間にレビューされていることを証明できるようになりました。JEPは、Judge、Verify、Delegate、Terminateという4つの暗号プリミティブを通じて、人間の介入に関する不変の...

新加坡--(BUSINESS WIRE)--(美国商业资讯)-- 人类判断系统基金会(HJS Foundation)今日发布两项互补解决方案：判断事件协议(JEP)和人类判断架构(HJS)框架。作为极简开放标准，JEP能生成防篡改的AI决策问责记录，如同飞机黑匣子一般；HJS则将人类判断逻辑嵌入AI运行流程——二者协同作用，将“人类监督”从监管要求转化为可验证的技术事实，为AI问责提供了可选技术方案。 如何证明AI决策（如贷款审批、医疗诊断、边境检查等）经过了人类审核？ JEP通过判断(Judge)、验证(Verify)、委托(Delegate)、终止(Terminate)四大加密原语，生成不可篡改的人类干预审计轨迹；HJS则构建可控、可问责的系统，防范AI漂移等风险，确保人类判断能指导AI运行。 当前系统依赖可修改的事后文档记录，而JEP和HJS则协同工作：JEP如同飞机黑匣子，不评判表现如何，只确保可追溯性；HJS则将人类监督嵌入AI工作流程——二者共同为监管机构、开发者和用户提供无可辩驳的事实依据。 JEP协议与HJS框架搭配使用，为可信AI提供了合规技术选项。它们共同实现了跨平...

新加坡--(BUSINESS WIRE)--(美國商業資訊)-- 人類判斷系統基金會(HJS Foundation)今日發表兩項互補解決方案：判斷事件協議(JEP)和人類判斷架構(HJS)體系。身為極簡開放標準，JEP能生成防篡改的AI決策問責記錄，如同飛機黑盒子一般；HJS則將人類判斷邏輯內建到AI運行流程中——二者協同作用，將「人類監督」從法規要求轉化為可驗證的技術事實，為AI問責提供了可選技術方案。 如何證明AI決策（如貸款批准、醫療診斷、邊境查驗等）經過了人類審核？ JEP透過判斷(Judge)、驗證(Verify)、委託(Delegate)、終止(Terminate)四大加密原語，生成不可篡改的人類介入稽核軌跡；HJS則建構可控、可問責的系統，防範AI漂移等風險，確保人類判斷能指導AI運行。 目前系統依賴可修改的事後文件記錄，而JEP和HJS則協同工作：JEP如同飛機黑盒子，不評判表現如何，只確保可追溯性；HJS則將人類監督內建到AI工作流程中——二者共同為主管機關、開發者和使用者提供無可辯駁的事實依據。 JEP協議與HJS架構搭配使用，為可信AI提供了法規遵循技術選項。它們...